The latest research news on alzheimer's disease, dementia
Alzheimer's disease is a progressive neurodegenerative disease estimated to affect 6 million Americans and 33 million people worldwide.
Large numbers of those affected have not yet been diagnosed.Wildfires and farming may pose threats to cognitive health, according to new research from the University of Michigan.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
New study offers preliminary estimates of mortality risk by stage in Alzheimer's diseaseResearchers examine the expected survival of people at each stage of Alzheimer's disease.
Weiterlesen »
Several vaccines associated with reduced risk of Alzheimer's disease in adults 65 and olderPrior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus are all associated with a reduced risk for developing Alzheimer's disease, according to new research from UTHealth Houston.
Weiterlesen »
Charity art sale organiser shares heartbreaking story behind choosing Alzheimer's Society as beneficiaryOne of the organisers of a unique charity art sale has spoken of the devastating impact dementia has had on her family.
Weiterlesen »
Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s diseaseThe association between Androgen Deprivation Therapy (ADT) and the risk of dementia.
Weiterlesen »
Only a small percentage of older adults with early Alzheimer's eligible for new treatmentsOnly a small percentage of older adults who are in the early stages of Alzheimer's disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer's disease.
Weiterlesen »
Only a small percentage of people with early dementia eligible for new Alzheimer's drugsOnly a small percentage of older adults who are in the early stages of Alzheimer's disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer's disease.
Weiterlesen »